Pharmacogenetic Testing and Chronic Pain
SuspendedNCT05259865
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
Understanding the impact of genetics could aid rational, precision drug choices. In the current study, investigators will focus on whether genetic analysis of drug processing using the Inagene platform could predict efficacy and side effect profile in patients prescribed medication for pain.
Study details
- Official title
- The Utility of Genetic Testing in Predicting Drug Response in Chronic Pain
- Conditions
- Interventions
- Diagnostic test: Genetic test for drug response prediction
- Sponsor
- Canadian Forces Health Services Centre Ottawa
- Start date
- 2025-09-21
- Primary completion
- 2026-12-31
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * male and female between 18 and 60 years old * seen within the CFO-P * diagnosed by a physician with one or more chronic pain condition. Exclusion Criteria: * adults who are unable to give their own consent * contraindications to a buccal swab * uncontrolled mental health issues determined by clinical judgement without mental health treatment and/or presence of active suicidal ideation
Canadian sites (1)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05259865